AstraZeneca PLC Add to portfolio

LON100:AZN, Feb 21, 08:33 UTC

Latest LON100:AZN News

Filter your feed

Apply Filter

Wednesday, February 19


News

Here’s why Astrazeneca is one of the most expensive shares on the market

AZN AZN

Here’s why Astrazeneca is one of the most expensive shares on the market. It has long been understood that cheap stocks have a tendency to outperform expensive stocks in the stock market. While this is not true every single year, over almost every 3-year cycle in the stock market, cheap (or value) stocks outperform. This phenomenon has created the cult of 'Value Investing' born of the writings of Benjamin Graham and the amazing success of its arch proponent Warren Buffett. In the 4th edition of his groundbreaking investment research tome What Works on Wall St, O’Shaughnessy shows that composite value factors based on a mix of metrics dramatically beat the market over a multi-decade period.

Read Full Details

Topics:
  • Business
  • Financial

Sunday, February 16


News

Why I’d avoid AstraZeneca shares and buy this FTSE 100 stock

AZN AZN

The AstraZeneca (LSE: AZN) share price has risen by more than 90% since May 2016 as investors have bought into CEO Pascal Soriot’s more focused strategy for the business. However, the shares dipped on Friday after Mr Soriot warned that 2020 earnings may be hit by the coronavirus outbreak. Core earnings of $3.50 per share were only slightly below broker forecasts of $3.59 per share. Although most companies use adjusted profits, I feel that AstraZeneca’s approach to calculating its core profits is aggressive and excludes some costs that should really be left in. The group’s core operating profit was $6,436m. But its reported operating profit, which includes all standard accounting costs, fell by 14% to $2,924m. This non-cash accounting charge relates to the gradual reduction in value of intellectual property such as patents, licences and software. As you can imagine, this kind of asset is a big part of a pharmaceutical business — AstraZeneca carries about $21bn of intangible assets on its balance sheet, reflecting historic spending.

Read Full Details

Topics:
  • Business
  • Financial

Saturday, February 15


News

AstraZeneca Announces Q4 Financial Results, Coronavirus Fears Weigh on Guidance

AZN AZN

Feb 14, 2020 8:14PM EST. AstraZeneca Announces Q4 Financial Results, Coronavirus Fears Weigh on Guidance | NASDAQ. AstraZeneca (NYSE: AZN) announced its fourth-quarter and 2019 full-year financial results on Friday morning. While the company reported impressive sales growth in a number of its top-selling drugs, investors are worried that the novel coronavirus outbreak could significantly eat away at the company's 2020 sales. Product sales accounted for the majority of this figure, around $6.25 billion, which is up a healthy 8.4% from Q4 2018. Another top performer for the company, a cancer drug called Imfinzi, is up 62% from Q4 2018 and brought in $424 million. The company's 2020 guidance expects high-single-digit to low-double-digit percentage increases in revenue assuming that the coronavirus doesn't last more than a few months.

Read Full Details

Story Sources

nasdaq.com fool.com
Topics:
  • Business
  • Health
  • Financial

Friday, February 14


News

AstraZeneca's (AZN) Q4 Earnings and Sales Miss Estimates

AZN AZN

ZacksFebruary 14, 2020, 2:21 PM UTC. AstraZeneca AZN reported dismal fourth-quarter results with earnings and sales both missing the Zacks Consensus Estimate. Fourth-quarter 2019 core earnings of 45 cents per American depositary share missed the Zacks Consensus Estimate of 53 cents. Among the newer medicines, Lynparza sales rose 69% year over year and 7.3% sequentially to $351 million in the quarter on the back of expanded use in ovarian and breast cancer, as well as solid growth in emerging markets. AstraZeneca markets Lynparza in partnership with Merck MRK. Sales of other legacy drugs including Zoladex, Arimidex, Atacand and Daliresp/Daxas grew in the quarter while sales of others like Faslodex, Casodex, and Synagis declined.

Read Full Details

Topics:
  • Business
  • Financial
News

AstraZeneca's CEO reaffirms 2021 targets

AZN AZN

LONDON (Reuters) - AstraZeneca <AZN.L> is fully on track to reach its earnings goal for next year, its chief executive told Reuters on Friday after the British drugmaker's quarterly earnings missed market expectations. "What we've said is that by 2021 we would cover the dividend in full and we would target an operating margin north of 30%. This is very much in line with what we are targeting," CEO Pascal Soriot said, following the release of fourth-quarter results. AstraZeneca is moving into a third year of sales growth after changes driven by Soriot and now has nine drugs with annual sales of more than $1 billion but analysts and investors have been looking for clues whether the company's earnings growth would keep up. The company's 2019 operating margin, or earnings before interest and tax over total revenue, was 26%. AstraZeneca's CEO reaffirms 2021 targets.

Read Full Details

Topics:
  • Business
  • Financial
News

What to Watch: AstraZeneca warns on coronavirus, RBS rebrand and markets' stimulus hopes

AZN AZN +2 more AZN AZN FB RBS

Here are the top business, market and economic stories you should be watching today in the UK, Europe, and abroad:. AstraZeneca warns on coronavirus. The UK drugmaker AstraZeneca (AZN.L) has warned it expects the coronavirus to hits its growth targets. Analysts had warned anything below double-digit sales growth marked a disappointment, according to Reuters. But Russ Mould, investment director at AJ Bell, said the 2019 results were “fairly decent.” He added that the company was focusing on developing treatments that were harder for rivals to replicate, after “suffering from over-reliance on blockbuster drugs” that later lost patent protection in the past. Royal Bank of Scotland (RBS.L) nearly doubled annual profits for the second year in a row on Friday, as new chief executive Alison Rose announced a sweeping new strategy and plans to rename the bank.

Read Full Details

Topics:
  • Business
  • Financial
News

Stocks - Europe Heads Lower; RBS, Renault, AstraZeneca Weigh

AZN AZN +2 more AZN AZN RBS RNO

Investing.com - European stock markets pushed lower Friday, with early gains overturned by losses in index heavyweights RBS (LON:RBS), Renault (PA:RENA) and AstraZeneca (LON:AZN). At 03:50 ET (0840 GMT), the U.K.'s FTSE index was trading 16 points, or 0.2%, lower, France's CAC 40 was down 11 points, also a 0.2% drop, while the DAX was largely flat. Shares in British banking group RBS (LON:RBS) slumped 5% despite reporting earnings significantly above expectations early Friday, prompting it to announce a special dividend after group net profit soared to 4.2 billion pounds. This follows Nissan, in which Renault is a major shareholder, cutting its annual profit forecast and canceling its dividend for the second half of the year. AstraZeneca shares (LON:AZN) dropped 1.5% after its core operating profit fell in the final quarter of the year, missing expectations.

Read Full Details

Topics:
  • Business
  • Financial
News

FTSE slips on poor earnings from AstraZeneca, RBS

AZN AZN +2 more AZN AZN TRI RBS

FTSE slips on poor earnings from AstraZeneca, RBS | NASDAQ. For a live blog on European stocks, type LIVE/ in an Eikon news window. FTSE 100 down 0.4%, FTSE 250 up 0.1%. AstraZeneca drops after profit miss. Feb 14 (Reuters) - UK blue-chip shares slipped further on Friday, weighed down by underwhelming results from AstraZeneca and RBS, while investors remained unsettled due to concerns over the impact of the coronavirus on the global economy. The FTSE 100 index .FTSE was 0.4% lower by 0805 GMT and was set to end the week with a near 1% fall, but the midcap bourse .FTMC rose 0.1% as it drew strength from the pound. As the epidemic in China shows no signs of peaking, global markets may look to central banks to step in and undertake stimulus measures.

Read Full Details

Topics:
  • Business
  • Financial
News

AstraZeneca braces for coronavirus hit, but no impact so far

AZN AZN

(Reuters) - AstraZeneca forecast a likely slowdown in revenue growth this year, assuming a hit from China's coronavirus epidemic lasting up to a few months, although it added there had been limited disruption to its operations so far. Shares in the company, one of the world's major drugmakers, tumbled as much as 6% in early Friday trade after fourth-quarter results also missed analysts' expectations. However, they recovered after CEO Pascal Soriot played down the impact of the coronavirus outbreak on the business so far. The company, moving into a third year of growth, predicted revenues would rise by a high single-digit to a low double-digit percentage at constant exchange rates this year, compared with 13% in 2019. "New drugs which were growth drivers all through 2019 posted below-expectations fourth-quarter sales," Berrigaud said. AstraZeneca forecast core earnings per share would rise by a mid- to high-teens percentage in 2020, compared with just 1% in 2019 and analysts' current consensus forecast of about 20%. Soriot also said the company was on track to reach an operating profit margin target of more than 30% in 2021.

Read Full Details

Topics:
  • Business
  • Financial
  • Health
News

AstraZeneca FY19 Core Operating Profit Rises; Sales Up 12% - Quick Facts

AZN AZN

Feb 14, 2020 2:28AM EST. AstraZeneca FY19 Core Operating Profit Rises; Sales Up 12% - Quick Facts | NASDAQ. (RTTNews) - AstraZeneca plc (AZN.L, AZN) reported profit before tax of $1.55 billion for the year ended 31 December 2019 compared to $1.99 billion, previous year. Core operating profit was $6.44 billion, an increase of 13%. New medicines represented 42% of total product sales. For fiscal 2020 at CER, depending on the impact of the coronavirus epidemic, AstraZeneca projects: core earnings per share to increase by a mid- to high-teens percentage; and revenue to increase by a high single-digit to a low double-digit percentage.

Read Full Details

Topics:
  • Business
  • Health
  • Financial